Cardiff Oncology Inc Total Liabilities
Cardiff Oncology Inc total liabilities. Based on the latest financial reports, Cardiff Oncology Inc (CRDF) has total liabilities worth $16.50 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Cardiff Oncology Inc liquidity resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Cardiff Oncology Inc (2009–2025)
Total liabilities of Cardiff Oncology Inc from 2009 to 2025. This chart illustrates how Cardiff Oncology Inc's total liabilities have evolved over time, based on quarterly financial data.
Cardiff Oncology Inc Competitors by Total Liabilities
The table below lists competitors of Cardiff Oncology Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Thai Wacoal Public Company Limited
BK:WACOAL
|
Thailand | ฿927.57 Million |
|
Greenheart Gold Inc.
V:GHRT
|
Canada | CA$2.24 Million |
|
KUYA SILVER CORP.
F:6MR1
|
Germany | €3.84 Million |
|
Azion Corporation
TWO:6148
|
Taiwan | NT$682.09 Million |
|
DHP Korea Co. Ltd
KQ:131030
|
Korea | ₩25.12 Billion |
|
S Connect Co. LTD
KQ:096630
|
Korea | ₩69.03 Billion |
|
Skane mollan AB
ST:SKMO
|
Sweden | Skr35.70 Million |
|
Herige SA
PA:ALHRG
|
France | €191.51 Million |
Liability Composition Analysis (2009–2025)
This chart breaks down Cardiff Oncology Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Cardiff Oncology Inc asset portfolio.
Liquidity & Leverage Metrics
Cardiff Oncology Inc Total Liabilities Ratios Explained
Cardiff Oncology Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.67 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.36 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.27 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Cardiff Oncology Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Cardiff Oncology Inc (2009–2025)
The table below shows the annual total liabilities of Cardiff Oncology Inc from 2009 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $16.50 Million | +15.83% |
| 2024-12-31 | $14.24 Million | +19.69% |
| 2023-12-31 | $11.90 Million | +20.82% |
| 2022-12-31 | $9.85 Million | +7.90% |
| 2021-12-31 | $9.13 Million | +38.94% |
| 2020-12-31 | $6.57 Million | +13.74% |
| 2019-12-31 | $5.78 Million | +41.27% |
| 2018-12-31 | $4.09 Million | -29.26% |
| 2017-12-31 | $5.78 Million | -76.10% |
| 2016-12-31 | $24.18 Million | +6.32% |
| 2015-12-31 | $22.75 Million | +10.69% |
| 2014-12-31 | $20.55 Million | +203.80% |
| 2013-12-31 | $6.76 Million | -28.77% |
| 2012-12-31 | $9.50 Million | +80.17% |
| 2011-12-31 | $5.27 Million | -4.30% |
| 2010-12-31 | $5.51 Million | +21.05% |
| 2009-12-31 | $4.55 Million | -- |
About Cardiff Oncology Inc
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers in the United States. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer. The company also focuses on the clinical program in indications, such as investigator-initiated trials in… Read more